Press releases

All Press releases are available in Swedish.

Interim report 2017-01-01 to 2017-06-30

Summary of interim report

Period (2017-01-01-2017-06-30)

  • Operating revenue KSEK 0 (0)
  • Income after financial items KSEK -4 075 (-1 626)
  • Earnings per share -0,27 (-0,13) SEK
  • Cash and cash equivalents, KSEK 28 114 (24 636) as of 2017-06-30
  • Equity ratio 95,2 (87,9) % as of 2017-06-30

Period (2017-04-01-2017-06-30)

  • Operating revenue KSEK 0 (0)
  • Income after financial items KSEK -2 588 (-1 157)
  • Earnings per share SEK -0,17 (-0,09) 

Significant events during the second quarter of 2017

  • Cyxone signed an agreement pertaining to the exclusive rights to acquire the clinical candidate drug Rabeximod from OxyPharma AB.
  • Cyxone AB and the University of Queensland in Australia entered into a co-operation agreement to further characterize the effects of Cyxone's T20K in treating MS.
  • Cyxone entered a long-term strategic co-operation agreement with Sourcia, a clinical contract research organization (CRO) with offices in Belgium, Germany, and the Netherlands.
  • A collaboration agreement has been made with Bachem AG in Switzerland to improve the synthesis of T20 and produce drug for non-clinical and clinical studies.

Significant events after the end of the period

  • No significant events after the end of the period

CEO Kjell Stenberg comments
Cyxone's focus has been on planning and preparation for the efficacy and safety studies required to obtain approval for clinical studies with T20K.

Through the agreement with Bachem, a leading Swiss manufacturer of peptide drugs, we are confident to obtain high-quality drug for clinical trials according to our timeline.

In co-operation with the University of Queensland in 2017 Cyxone will perform a series of studies in the mouse-MS model to demonstrate T20K's potential to prevent development of MS symptoms. 

Toxicity studies are conducted in co-operation with the leading safety company LPT Technologies in Germany to establish a safe and innovative dosing of T20K.

In line with Cyxone's plans to initiate a second project in the autoimmune area the company agreed with OxyPharma to acquire Rabeximod for rheumatoid arthritis. Cyxone plans to conduct a phase IIb study in patients starting in 2018. To support the new clinical program starting in 2018 Cyxone enjoys constructive discussions with its investor network.

Follow our news and information about our presence at investor meetings via First North, and the company's webpage:

Kjell Stenberg
CEO, Cyxone AB

Upcoming financial reports
2017-10-25 Interim report Q3
2018-02-16 Year-end report

Malmo August 30, 2017

Board of Directors
Cyxone AB

Cyxone AB (publ)
Kjell G. Stenberg, CEO
Tel: 0723-816168
Adelgatan 21
211 22 Malmö

This year-end report is such information Cyxone AB is obligated to publish under the EU Market Abuse Regulation and Securities Markets Act. The information was released by CEO Kjell Stenberg for publication August 30, 2017 at. 08:50 CET.

This report contains forward-looking statements, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as of the date they are made and are, by their nature, as well as research and development work in the biotech segment, associated with risk and uncertainty. The actual outcome may deviate significantly from the scenarios described in this press release.

February 16, 2018

Summary of the Year-end Report

Fourth Quarter (1 October to 31 December 2017)

  • Operating revenue KSEK 0 (21)
  • Income after financial items KSEK -3 231 (-1 301)
  • Earnings per share -0,18 (-0,10)
  • Cash and cash equivalents as of 31 December KSEK 33 357 (21 598)
  • Equity ratio as of 31 December 90,4 (96,9) %

Financial year (1 January to 31 December 2017)

  • Operating revenue KSEK 0 (21)
  • Income after financial items KSEK -8 824 (-4 162)
  • Earnings per share SEK -0,50 (-0,32)
Read more
January 31, 2018

In response to interest from drug companies, Cyxone is to review whether cyclotides are effective against inflammatory bowel disease (IBD). The study was planned by the Medical University of Vienna and is now underway.

Read more
December 11, 2017

Today, December 11, 2017, Cyxone AB (publ.) held an extraordinary general meeting. Below is an overview of the motions decided upon. All motions were taken with the necessary majority of votes.

Read more
November 23, 2017

Shareholders in Cyxone AB (publ.), 559020-5471, are hereby invited to an extraordinary general meeting at Setterwalls Advokatbyrå AB, Stortorget 23, in Malmö, on Monday, December 11, 2017 at 10:00AM.

Read more
November 23, 2017

As previously announced, Cyxone acquired Rabeximod from OxyPharma in June 2017. Rabeximod has undergone Phase 2 trials in patients with moderate to severe rheumatoid arthritis in which significant improvements in the condition's symptoms were discovered four weeks after the completion of the formal (12 week) trial period.

Read more
November 06, 2017

Cyxone has analysed the Rabeximod that was previously manufactured by OxyPharma for clinical trials at Syntagon AB. Results show that the existing substance, despite having been stored for several years, can be used in Cyxone's upcoming Phase 2b study in patients with rheumatoid arthritis.

Read more
October 26, 2017


Period (July 1 to September 30, 2017)

  • Operating revenue KSEK 0 (0)
  • Income after financial items KSEK -1,518 (-1,235)
  • Earnings per share SEK -0,10 (-0,10) Cash and cash equivalents as of September 30 KSEK 25,662 (23,468)
  • Equity ratio as of September 30 95.2% (97.7%)

Period (January 1 to September 30)

  • Operating revenue KSEK 0 (0)
  • Income after financial items KSEK -5,593 (-2,860)
  • Earnings per share SEK -0,36 (-0,22)
Read more
October 26, 2017
In co-operation with Taiwan-based Eurofins Panlabs Discovery Services, Cyxone has investigated whether T20K has the capacity to influence receptors or other cellular functions to shed light on the substance's potential side effects.
Read more
October 13, 2017

In collaboration with the Medical University of Vienna, Cyxone is set to conduct a study into inflammatory bowel disease involving a cyclotide in established animal models. The study will begin early in 2018.

Read more